China Biologic Products Holdings, Inc.
CBPO
CBPO was delisted on the 20th of April, 2021.
119 hedge funds and large institutions have $2.25B invested in China Biologic Products Holdings, Inc. in 2017 Q2 according to their latest regulatory filings, with 10 funds opening new positions, 44 increasing their positions, 52 reducing their positions, and 27 closing their positions.
3,307% more call options, than puts
Call options by funds: $51.5M | Put options by funds: $1.51M
25% more funds holding in top 10
Funds holding in top 10: 4 → 5 (+1)
11% more capital invested
Capital invested by funds: $2.02B → $2.25B (+$232M)
13% less funds holding
Funds holding: 137 → 119 (-18)
15% less repeat investments, than reductions
Existing positions increased: 44 | Existing positions reduced: 52
63% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 27
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HIM
Hillhouse Investment Management
Grand Cayman,
Cayman Islands
|
+$54.9M |
| 2 |
Schroder Investment Management Group
London,
United Kingdom
|
+$53.9M |
| 3 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
+$35.2M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$20.6M |
| 5 |
CGI
Comgest Global Investors
Paris,
France
|
+$16.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital World Investors
Los Angeles,
California
|
-$58.7M |
| 2 |
Mirae Asset Global Investments
Seoul,
South Korea
|
-$20.5M |
| 3 |
Janus Henderson Group
London,
United Kingdom
|
-$18.9M |
| 4 |
Renaissance Technologies
New York
|
-$18.7M |
| 5 |
MWNA
Marshall Wace North America
New York
|
-$14.3M |
CBPO Hedge Fund Activity: Q2 2017 in Review
119 of the 4,012 institutional investors tracked by Wall St. Rank reported a position in China Biologic Products Holdings, Inc. (CBPO) for Q2 2017, worth a combined $2.25B — up 11% from $2.02B a quarter earlier.
Sellers outnumbered buyers: 27 funds closed out of CBPO and 10 opened new positions — a net loss of 17 holders — while 52 trimmed existing stakes and 44 added.
The largest buyer was Hillhouse Investment Management, adding an estimated $54.9M. The largest seller was Capital World Investors, cutting an estimated $58.7M.
- 119 institutional investors held China Biologic Products Holdings, Inc. (CBPO) as of Q2 2017, down from 137 in Q1 2017.
- Funds reported $2.25B of China Biologic Products Holdings, Inc. stock for Q2 2017, up 11% quarter-over-quarter.
- 10 funds opened new China Biologic Products Holdings, Inc. positions in Q2 2017 and 27 closed out, a net change of -17 holders.
- The largest China Biologic Products Holdings, Inc. buyer in Q2 2017 was Hillhouse Investment Management, an estimated $54.9M added.
- The largest China Biologic Products Holdings, Inc. seller in Q2 2017 was Capital World Investors, an estimated $58.7M sold.
Based on aggregated 13F filings for Q2 2017.